(Q44243828)

1 December 2017

Long-term survival in phase II trials of gemcitabine plus cisplatin for advanced transitional cell cancer (English)

1 reference

1 December 2017

phase II clinical trial

0 references

1 reference

5

Luigi Dogliotti

1 reference

1 December 2017

Walter M Stadler

1

1 reference

1 December 2017

Annamaria Hayden

2

1 reference

1 December 2017

Hans von der Maase

3

1 reference

1 December 2017

Debasish Roychowdhury

4

1 reference

1 December 2017

Lesley Seymour

6

1 reference

1 December 2017

Donald Kaufmann

7

1 reference

1 December 2017

Malcolm Moore

8

1 reference

1 December 2017

1 July 2002

1 reference

1 December 2017

1 reference

1 December 2017

7

1 reference

1 December 2017

153-157

1 reference

1 December 2017

4

1 reference

M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium.

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900182-5

7 January 2021

A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900182-5

7 January 2021

A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900182-5

7 January 2021

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900182-5

7 January 2021

Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900182-5

7 January 2021

Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900182-5

7 January 2021

Gemcitabine in locally advanced and/or metastatic bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900182-5

7 January 2021

Progress in the management of metastatic bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900182-5

7 January 2021

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900182-5

7 January 2021

Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900182-5

7 January 2021

Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900182-5

7 January 2021

Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900182-5

7 January 2021

Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900182-5

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900182-5

7 January 2021

Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900182-5

7 January 2021

Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1078-1439%2802%2900182-5

7 January 2021

10.1016/S1078-1439(02)00182-5

Identifiers

DOI

1 reference

1 December 2017

1 reference